Showing results (631-640 of 644) with videos related to

Sort By:
Pageof 65
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervixA P Kudelka, T Levy, C F Verschraegen, et al.
Addictive Behaviors|May 23, 2022
Differences in cigarette smoking quit attempts and cessation between adults who did and did not take up nicotine vaping: Findings from the ITC four country smoking and vaping surveysShannon Gravely, Gang Meng, David Hammond, et al.
BMJ Open|March 26, 2025
Implementation of the American- College of Physicians Guideline for Low Back Pain (IMPACt-LBP): protocol for a healthcare systems embedded multisite pragmatic cluster-randomised trialAdam P Goode, Christine Goertz, Hrishikesh Chakraborty, et al.
BMC Gastroenterology|July 12, 2022
Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-upPaul J Clark, Patricia C Valery, James Ward, et al.
Gynecologic Oncology|September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trialMansoor R Mirza, B Benigno, A Dørum, et al.
The Journal of Infectious Diseases|November 15, 2025
Anti-HBs immune complex levels: A novel marker of hepatitis flare following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis BS J Hume, K Visvanathan, K Cheng, et al.
Alimentary Pharmacology & Therapeutics|May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levelsSamuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancerT Van Gorp, D Cibula, W Lv, et al.
Pageof 65